RxDoctor Payments Data

Monika McLain, MD

Internal Medicine · Libertyville, ILNPI 1376539718

Payments from drug & device makers

$695in general payments, 2019–2025

Across 13 payments — averaging $53.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$252
  • Abbott$138
  • AbbVie$111
  • Novo Nordisk$100
  • Baxter Healthcare$61
  • Lilly USA, LLC$19
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$67197%
  • Education$243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$252
Abbott1$138
AbbVie4$111
Novo Nordisk1$100
Baxter Healthcare2$61
Lilly USA, LLC1$19
AstraZeneca1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$135,566
Medicare patients
414
Services billed
1,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$85,907
TrulicityDulaglutide32$53,934
JardianceEmpagliflozin33$50,926
RybelsusSemaglutide31$46,009
EliquisApixaban36$44,054
MounjaroTirzepatide32$42,840
XareltoRivaroxaban19$13,971
SynthroidLevothyroxine Sodium101$9,066
MyrbetriqMirabegron11$6,700
Breo ElliptaFluticasone/Vilanterol11$4,503
Spironolactone-HctzSpironolact/Hydrochlorothiazid113$4,312
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$4,235
Levothyroxine Sodium434$4,220
Nebivolol Hcl71$4,032
Estradiol54$3,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$100$131,91687 claims
Lilly USA, LLCTrulicity, Mounjaro$19$96,77464 claims
AbbVieSynthroid, Armour Thyroid$111$9,998113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →